



PRESS RELEASE

8 April 2026

Recipharm reports strong 2025 sustainability performance, advancing industry leadership

- *B rating for Climate Change, A- for Water Security and A for Supplier Engagement Assessment from CDP*
- *20% reduction in Scope 1 and 74% in Scope 2 emissions (vs 2021), with 100% renewable electricity across all sites*
- *Zero surface water withdrawal; advanced circularity with 13 sites already landfill-free*
- *Helping customers reduce Scope 3 emissions while delivering high quality medicines to patients.*

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced strong 2025 sustainability results, underscoring its position as a leader in sustainable pharmaceutical manufacturing.

The company continued to turn ambition into action, delivering measurable progress across its global operations. In 2025, Recipharm reduced Scope 1 greenhouse gas emissions by 20% and Scope 2 by 74% versus its 2021 baseline, while maintaining 100% renewable electricity across all sites.

Operational improvements are driving greater efficiency and lower environmental impact. Total water withdrawal decreased by 13% since 2022, with zero surface water withdrawal achieved. Circularity also advanced, with 63% of incinerated waste recovered for energy, and 13 out of 17 sites are now landfill-free, keeping Recipharm firmly on track to eliminate landfill across all sites by 2027.

This performance is backed by strong external recognition. In 2025, Recipharm achieved a B rating for Climate Change, A- for Water Security and A for Supplier Engagement Assessment from CDP, reflecting continued progress across its environmental and supply chain initiatives.

Greg Behar, CEO at Recipharm said: "Sustainability is a defining part of who we are at Recipharm. In 2025, our commitment translated into tangible progress and clear leadership, demonstrating that responsible pharmaceutical development and manufacturing can go hand in hand with strong operational performance. We are proud of the measurable results we have achieved and remain focused on accelerating progress across our global operations and value chain."

Beyond its own operations, Recipharm is driving impact across the pharmaceutical value chain. By partnering closely with customers, the company supports the reduction of Scope 3 emissions through more sustainable materials, optimised packaging, and more efficient manufacturing processes, helping lower the footprint of medicines delivered to patients worldwide.

At the same time, Recipharm continues to invest in its employees, strengthening health and safety, employee engagement and skills development, while maintaining the highest standards of product quality and reliability.

By combining sustainability leadership with operational excellence, Recipharm continues to deliver solutions that not only reduce environmental impact but also support better outcomes for customers, patients and the broader healthcare ecosystem.



Ends)

For more information

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 4,500 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Recipharm Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Italy, Portugal, Spain, Sweden and the US.

For more information about Recipharm, please visit www.recipharm.com and www.recipharm-ab.com

Media contact:

Guenaelle Holloway, Head of marketing and communications
Guenaelle.Holloway@recipharm.com
+44 7730 303 708